ArticleCurrent medical science2023

Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.

Xu Tan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.